Cerulean secures much-needed cash | Chemical & Engineering News
Volume 94 Issue 43 | p. 13 | Concentrates
Issue Date: October 31, 2016

Cerulean secures much-needed cash

Department: Business
Keywords: biotechnology, Cerulean, Novartis

Sinking Cerulean Pharma has found a way to stay afloat. Aspire Capital will buy $20 million worth of stock, providing much-needed cash to help move forward Cerulean’s two lead drug candidates. And in a separate move, Novartis will pay $5 million up front to use the biotech’s nanoparticle-drug conjugate technology to create drug candidates against up to five targets. Cerulean trimmed half its staff in August after its lead program, CRLX101, failed to show efficacy against kidney cancer in a Phase II study.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment